JP2018519356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519356A5 JP2018519356A5 JP2018506815A JP2018506815A JP2018519356A5 JP 2018519356 A5 JP2018519356 A5 JP 2018519356A5 JP 2018506815 A JP2018506815 A JP 2018506815A JP 2018506815 A JP2018506815 A JP 2018506815A JP 2018519356 A5 JP2018519356 A5 JP 2018519356A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- domain
- car
- genetically modified
- kma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 52
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 108700013903 SANT-7 Proteins 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 18
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 17
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 17
- 230000000139 costimulatory effect Effects 0.000 claims description 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 230000004068 intracellular signaling Effects 0.000 claims description 14
- 125000006850 spacer group Chemical group 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 claims 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical group NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 88
- 108091026890 Coding region Proteins 0.000 description 11
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 7
- 229940125754 MDX-1097 Drugs 0.000 description 7
- 210000003705 ribosome Anatomy 0.000 description 7
- 102100026019 Interleukin-6 Human genes 0.000 description 5
- 238000011476 stem cell transplantation Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 150000001255 actinides Chemical group 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical group CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022209702A JP2023024793A (ja) | 2015-04-23 | 2022-12-27 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151968P | 2015-04-23 | 2015-04-23 | |
| US62/151,968 | 2015-04-23 | ||
| US201562158407P | 2015-05-07 | 2015-05-07 | |
| US62/158,407 | 2015-05-07 | ||
| PCT/US2016/029203 WO2016172703A2 (en) | 2015-04-23 | 2016-04-25 | Kappa myeloma antigen chimeric antigen receptors and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021020594A Division JP2021073312A (ja) | 2015-04-23 | 2021-02-12 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
| JP2022209702A Division JP2023024793A (ja) | 2015-04-23 | 2022-12-27 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519356A JP2018519356A (ja) | 2018-07-19 |
| JP2018519356A5 true JP2018519356A5 (enExample) | 2019-06-06 |
| JP7229768B2 JP7229768B2 (ja) | 2023-02-28 |
Family
ID=57143653
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506815A Active JP7229768B2 (ja) | 2015-04-23 | 2016-04-25 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
| JP2021020594A Pending JP2021073312A (ja) | 2015-04-23 | 2021-02-12 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
| JP2022209702A Withdrawn JP2023024793A (ja) | 2015-04-23 | 2022-12-27 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021020594A Pending JP2021073312A (ja) | 2015-04-23 | 2021-02-12 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
| JP2022209702A Withdrawn JP2023024793A (ja) | 2015-04-23 | 2022-12-27 | カッパ骨髄腫抗原キメラ抗原受容体およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11305011B2 (enExample) |
| EP (2) | EP4368641A3 (enExample) |
| JP (3) | JP7229768B2 (enExample) |
| KR (1) | KR102623427B1 (enExample) |
| CN (1) | CN107922489B (enExample) |
| AU (1) | AU2016253126B2 (enExample) |
| BR (1) | BR112017022838A2 (enExample) |
| CA (1) | CA2978964A1 (enExample) |
| DK (1) | DK3286223T5 (enExample) |
| ES (1) | ES2976236T3 (enExample) |
| FI (1) | FI3286223T3 (enExample) |
| HK (1) | HK1252854A1 (enExample) |
| HR (1) | HRP20240415T1 (enExample) |
| HU (1) | HUE065799T2 (enExample) |
| IL (1) | IL255207B2 (enExample) |
| PT (1) | PT3286223T (enExample) |
| RU (1) | RU2743188C2 (enExample) |
| WO (1) | WO2016172703A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4368641A3 (en) | 2015-04-23 | 2024-08-14 | HaemaLogiX Ltd. | Kappa myeloma antigen chimeric antigen receptors and uses thereof |
| CN107529550A (zh) * | 2017-08-28 | 2018-01-02 | 马晓冬 | 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法 |
| WO2019047932A1 (zh) * | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| WO2019108932A1 (en) * | 2017-11-30 | 2019-06-06 | Haemalogix Pty. Ltd. | Methods for expanding kappa myeloma antigen chimeric antigen receptors expressing cells |
| WO2019201995A1 (en) * | 2018-04-20 | 2019-10-24 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
| JPWO2020004337A1 (ja) * | 2018-06-27 | 2021-08-02 | 国立大学法人東海国立大学機構 | Ｃｄ３７特異的キメラ抗原レセプター |
| US20220177573A1 (en) | 2018-07-09 | 2022-06-09 | Oslo Universitetssykehus Hf | Two chimeric antigen receptors specifically binding cd19 and igkappa |
| CN110832071A (zh) * | 2018-09-14 | 2020-02-21 | 上海原能细胞医学技术有限公司 | 表面包含免疫调节剂的细胞及其用途 |
| EP3890780A4 (en) * | 2018-12-03 | 2022-08-17 | HaemaLogiX Pty Ltd. | METHOD OF TREATMENT |
| US20220175833A1 (en) * | 2019-03-07 | 2022-06-09 | Children's Medical Center Corporation | Targeted delivery of immune-modulating vhh and vhh-fusion protein |
| KR20220012328A (ko) * | 2019-05-24 | 2022-02-03 | 포티 세븐, 인코포레이티드 | c-kit 및 CD47에 대한 면역요법제의 병용 투여를 위한 요법 |
| CN110305906B (zh) * | 2019-07-18 | 2021-11-12 | 山东大学第二医院 | 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞 |
| KR20220137882A (ko) * | 2019-12-05 | 2022-10-12 | 바이셀릭스, 인크. | 보편적 세포 요법을 위한 면역 회피 기작의 조절제 |
| CA3176109A1 (en) * | 2020-03-27 | 2021-09-30 | Haemalogix Pty Ltd | Composition and method |
| IL297851A (en) | 2020-05-04 | 2023-01-01 | Saliogen Therapeutics Inc | Transposition-based treatments |
| WO2021232200A1 (en) * | 2020-05-18 | 2021-11-25 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Il-12 armored immune cell therapy and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022268196A1 (zh) * | 2021-06-25 | 2022-12-29 | 天辰生物医药(苏州)有限公司 | 靶向gpc3的抗原结合蛋白 |
| WO2023010118A1 (en) * | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same |
| KR102789265B1 (ko) * | 2022-04-14 | 2025-04-02 | 주식회사 셀랩메드 | 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법 |
| WO2024196796A1 (en) * | 2023-03-17 | 2024-09-26 | Cartesian Therapeutics, Inc. | Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors |
| WO2025136986A2 (en) | 2023-12-18 | 2025-06-26 | Genzyme Corporation | Il-12 loss of potency muteins |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR617901A0 (en) | 2001-07-06 | 2001-08-02 | Pacmab Pty Ltd | Method for treating multiple myeloma |
| CA2507080C (en) * | 2002-11-27 | 2015-01-06 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
| WO2007019406A2 (en) * | 2005-08-04 | 2007-02-15 | The Regents Of The University Of California | Methods for treating and detecting beta-cell disease |
| SG175106A1 (en) | 2009-04-07 | 2011-11-28 | Immune System Therapeutics Ltd | Method for treating immune disorders |
| WO2010135655A2 (en) * | 2009-05-21 | 2010-11-25 | Stratatech Corporation | Human skin substitutes expressing il-12 |
| US9212229B2 (en) | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| US20140322216A1 (en) * | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| WO2014100689A1 (en) * | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| CN104177499B (zh) * | 2013-05-27 | 2019-01-08 | 上海雅科生物科技有限公司 | 一种嵌合抗原受体、编码基因、表达载体及其应用 |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| WO2015164739A1 (en) * | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Kappa/lambda chimeric antigen receptors |
| EP4368641A3 (en) | 2015-04-23 | 2024-08-14 | HaemaLogiX Ltd. | Kappa myeloma antigen chimeric antigen receptors and uses thereof |
-
2016
- 2016-04-25 EP EP24151551.9A patent/EP4368641A3/en active Pending
- 2016-04-25 IL IL255207A patent/IL255207B2/en unknown
- 2016-04-25 DK DK16784085.9T patent/DK3286223T5/da active
- 2016-04-25 WO PCT/US2016/029203 patent/WO2016172703A2/en not_active Ceased
- 2016-04-25 PT PT167840859T patent/PT3286223T/pt unknown
- 2016-04-25 CN CN201680031653.3A patent/CN107922489B/zh active Active
- 2016-04-25 CA CA2978964A patent/CA2978964A1/en active Pending
- 2016-04-25 JP JP2018506815A patent/JP7229768B2/ja active Active
- 2016-04-25 HK HK18112185.0A patent/HK1252854A1/zh unknown
- 2016-04-25 US US15/568,271 patent/US11305011B2/en active Active
- 2016-04-25 BR BR112017022838A patent/BR112017022838A2/pt active Search and Examination
- 2016-04-25 HR HRP20240415TT patent/HRP20240415T1/hr unknown
- 2016-04-25 RU RU2017138528A patent/RU2743188C2/ru active
- 2016-04-25 AU AU2016253126A patent/AU2016253126B2/en active Active
- 2016-04-25 FI FIEP16784085.9T patent/FI3286223T3/fi active
- 2016-04-25 KR KR1020177032005A patent/KR102623427B1/ko active Active
- 2016-04-25 EP EP16784085.9A patent/EP3286223B8/en active Active
- 2016-04-25 HU HUE16784085A patent/HUE065799T2/hu unknown
- 2016-04-25 ES ES16784085T patent/ES2976236T3/es active Active
-
2021
- 2021-02-12 JP JP2021020594A patent/JP2021073312A/ja active Pending
-
2022
- 2022-02-28 US US17/682,276 patent/US20220193232A1/en active Pending
- 2022-12-27 JP JP2022209702A patent/JP2023024793A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519356A5 (enExample) | ||
| RU2017138528A (ru) | Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения | |
| US20220340676A1 (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| US20220177595A1 (en) | Multimeric gitr binding molecules and uses thereof | |
| US20210388098A1 (en) | Multimeric cd137/4-1bb binding molecules and uses thereof | |
| US9200078B2 (en) | Antibodies against prostate-specific stem cell antigen and use thereof | |
| RU2355705C2 (ru) | Одноцепочечное цикличное триспецифическое антитело | |
| CN108136012A (zh) | 靶向分子的抗原结合构建体 | |
| WO2017127702A1 (en) | Ror2 antibody compositions and related methods | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| CA3146019A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| CA3030647A1 (en) | Multimeric ox40 binding molecules and uses thereof | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2020512973A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| MX2020012081A (es) | Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. | |
| CA3240254A1 (en) | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors | |
| WO2023155852A1 (zh) | 经修饰的免疫效应细胞及其用途 | |
| NZ735778B2 (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
| JPWO2022212879A5 (enExample) | ||
| Canevari et al. | Anti-FR Antibody Generation and Engineering: Development of New Therapeutic Tools |